Keywords: merck, co, 3rd-qtr, eps, drops, restructuring, further
Merck & Co's 3rd-qtr EPS drops 27% on restructuring; further downsizing to come
Article | 03 November 2008
US drug major Merck & Co's third-quarter 2008 earnings per share dropped 27.1% year-on-year to $0.51 due to a heavy $0.29 per share restructuring charge ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
